European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non …
S Saussele, J Richter, J Guilhot, FX Gruber… - The Lancet …, 2018 - thelancet.com
Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …
Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Hochhaus, S Saussele, G Rosti… - Annals of …, 2017 - annalsofoncology.org
The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15
cases/106/year without any major geographic or ethnic differences [1]. The median age at …
cases/106/year without any major geographic or ethnic differences [1]. The median age at …
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
D Rea, FE Nicolini, M Tulliez, F Guilhot… - Blood, The Journal …, 2017 - ashpublications.org
Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …
Moving treatment-free remission into mainstream clinical practice in CML
The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …
perception that chronic myeloid leukemia (CML) has become another chronic disease …
The concept of treatment-free remission in chronic myeloid leukemia
S Saußele, J Richter, A Hochhaus, FX Mahon - Leukemia, 2016 - nature.com
The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …
Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
S Mori, E Vagge, P Le Coutre… - American journal of …, 2015 - Wiley Online Library
Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even
undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease …
undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease …